Viridian Therapeutics, Inc.
corporate_fare Company Profile
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for VRDN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 17 rated 8 or above. Recent SEC coverage for VRDN spans 8-K, 10-Q, 4, SCHEDULE 13D/A.
Recent high-impact activity:
- VRDN-008 Phase 1 Hits 74% IgG Reduction, Every-8-Week Dosing Possible
- Viridian Q3: Lumvoa Launch Hits $24.7M, Cash $955M, Elegrobart BLA Set for Q1 2027
- Lumvoa's First Launch Quarter Brings $24.7M, Beating Management's Own Expectations
- Viridian Posts $127M Q2 Loss, $982M Cash; Lumvoa Launch Underway After FDA Nod
- Viridian Posts $69.72/Share Q1 Loss, Deepening Cash Burn
Financial Snapshot
Short Interest & Short Volume
9.07 days to coverFINRA reported short interest of 17,042,236 shares in VRDN as of the October 30, 2026 settlement, a 5.3% decrease from the prior period — about 9.1 days to cover at its recent average daily volume. On November 20, 2026, 48.1% of VRDN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.